DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20204104

A study on efficacy of ambroxol in the treatment of acute bronchitis in tertiary care hospital

V. Jaya Wardhani, Nagawaram P. Rao

Abstract


Background: Upper respiratory tract infections (URTI), including acute bronchitis, are the frequent health problems and the most common reason for acute cough in adults. Even though the infections are caused mainly by viruses, and their course is usually not complicated, febrifuges, i.a. mucokinetics, or antitussives are used in the treatment of URTI in order to improve the quality of life and safety of patients.

Methods: The present study was prospective and observational study. Data from adult patients treated with ambroxol hydrochloride for acute bronchitis were collected and compared with data from patients treated for the same condition without ambroxol preparations. The severity of bronchitis symptoms was evaluated with the respiratory rate, retraction score, wheezing score and oxygen saturation (SPO2) between visits patients conducted self-observations and filled out observation diaries. Baseline clinical symptomatolgy of breathlessness, cough, and sputum severity scoring were compared before and after 3 and 7 days of treatment in both groups.

Results: Majority of the patient’s infections were cured. Most of patients considered the studied drugs to be the agent decreasing the duration of infection and its intensity. The percentage of patients who declared that they had a less intense cough than during earlier infections was higher in the group of patients treated with ambroxol treated patients. Patients treated with Ambroxol hydrochloride to be very safe.

Conclusions: Ambroxol is an efficient, well-tolerated, and safe drug. Its efficacy in the treatment of acute bronchitis symptoms in adult patients is similar to the efficacy of other preparations.


Keywords


Ambroxol, Bronchitis, Efficacy, Oxygen saturation

Full Text:

PDF

References


Wunderer H, Morgenroth K, Weis G. The cleaning system of the airways: physiology, pathophysiology and effects of ambroxol. Med Monatsschr Pharm. 2009;32:42-7.

Malerba M, Ragnoli B. Ambroxol in the 21st century:pharmacological and clinical update. Expert Opin Drug Metab Toxicol. 2008;4:1119-29.

Li Q, Yao G, Zhu X. High-dose ambroxol reduces pulmonary complications in patients with acute cervical spinalcord injury after surgery. Neurocrit Care. 2012;16:267-72.

Wauer RR, Schmalisch G, Böhme B, Arand J, Lehmann D. Randomized double blind trial of Ambroxol for the treatment of respiratory distress syndrome. Europ J Pediatr. 1992;151(5):357-63.

Xia DH, Xi L, Xv C, Mao WD, Shen WS, Shu ZQ, et al. The protective effects of ambroxol on radiation lung injury and influence on production of transforming growth factor β 1 and tumor necrosis factor α. Medic Oncol. 2010;27(3):697-701.

Ulas MM, Hizarci M, Kunt A, Ergun K, Kocabeyoglu SS, Korkmaz K, et al. Protective effect of ambroxol on pulmonary function after cardiopulmonary bypass. J Cardiovascu Pharmacol. 2008;52(6):518-23.

Wang Y, Wang FY, Pan Z, Dai YY, Xu HJ, Jin KK, et al. Effects of ambroxol combined with low-dose heparin on TNF-alpha and IL-1beta in rabbits with acute lung injury. J Appli Physiol. 2011;27(2):231-5.

Su X, Wang L, Song Y, Bai C. Inhibition of inflammatory responses by ambroxol, a mucolytic agent, in a murine model of acute lung injury induced by lipopolysaccharide. Intensi Care Medic. 2004;30(1):133-40.

Ma YT, Tian YP, Shi HW, Lv CH, Liu JH, Sun ZP. Effects of high dose ambroxol on lung injury induced by paraquat in rats. Chine J Indust Hygie Occupat Diseas. 2007;25(9):523.

ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome:the Berlin Definition. Ameri Medic Assoc. 2012;307:2526-33.

Schulz M, Hammrlein A, Hinkel U. Safety and usage pattern of an over-the-counter ambroxol cough syrup: a community pharmacy based cohort study. Int J Clin Pharmacol Ther. 2006;44:409-21.

Schmalisch G, Wauer RR, Bohme B. Effect of early ambroxol treatment on lung functions in mechanically ventilated preterm newborns who subsequently developed a bronchopulmonary dysplasia. Respir Med. 2000;94:378-84.

Ericsson CH, Juhasz J, Jönsson E, Mossberg B. Ambroxol therapy in simple chronic bronchitis: effects on subjective symptoms and ventilatory function. Europ J Respirat Diseas. 1986;69(4): 248-55.

Balter MS, La Forge J, Low DE, Mandell L, Grossman RF, Chronic Bronchitis Working Group. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. Canadi Respirat J. 2003;10.